| 價(jià)格 | 詢價(jià) |
| 包裝 | 1removed |
| 最小起訂量 | 1removed |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-04-02 |
| 中文名稱:化合物 ML241 hydrochloride | 英文名稱:ML241 hydrochloride |
| CAS:2070015-13-1 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 純度規(guī)格: 99.97% | 產(chǎn)品類別: 抑制劑 |
| 貨號: T4684 |
| 名稱 | ML241 hydrochloride |
| 描述 | ML241 is a potent and selective inhibitors of p97 ATPase.ML241 inhibits degradation of a p97-dependent but not a p97-independent proteasome substrate in a dual-reporter cell line. ML241 may be a novel agent for the chemotherapy of cancer, and provide a rationale for developing pathway-specific p97 inhibitors. |
| 細(xì)胞實(shí)驗(yàn) | HeLa cells stably expressing ODD-luciferase are seeded onto a 96-well white solid bottom plate (5000 cells/well) and cells are grown for 16 h. Cells are treated with DMEM containing MG132 (4 μM) for 1h and washed with 100 μL PBS twice. DMEM containing 2.5% FBS, cycloheximide (50 μg/mL) and ML241 are added into the well. Four 96-well plates are prepared and one of the plates is taken out from incubator at each time point (70, 90, 120, or 150 min). Luciferin (50 μL of 1 mg/mL in PBS) is added into each well containing 50 μL of medium and incubated at room temperature with shaking at 500 rpm for 5 min. Luminescence intensity is determined with 0.1 ms integration time on the Synergy HT Microplate Reader |
| 體外活性 | ML241對HCT15和SW403細(xì)胞表現(xiàn)出細(xì)胞毒性,其GI50分別為經(jīng)過24小時(shí)處理后的53μM和33μM,以及經(jīng)過72小時(shí)處理后的13μM和12μM。 |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 50 mg/mL (122.27 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.89 mM), Sonication is recommended. |
| 關(guān)鍵字 | VCP | p97 | ML-241 hydrochloride | ML241 hydrochloride | ML-241 | ML241 | ML 241 Hydrochloride | ML 241 | Inhibitor | inhibit | Cdc48 |
| 相關(guān)產(chǎn)品 | CB-5083 | NSC799462 | VCP/p97 IN-2 | MNS | MSC1094308 | NMS-859 | NMS-873 | NPD8733 | Eeyarestatin I | CB-5339 | DBEQ | ML240 |
| 相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 抗癌化合物庫 | 已知活性化合物庫 | 抗感染化合物庫 | HIF-1化合物庫 | NO PAINS 化合物庫 | 抗病毒庫 | 泛素化化合物庫 | 內(nèi)質(zhì)網(wǎng)應(yīng)激化合物庫 |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 566.265100萬人民幣 |
| 員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| 詢價(jià) |
VIP1年
|
陜西締都醫(yī)藥有限責(zé)任公司
|
2026-06-09 | |
| 詢價(jià) |
VIP5年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2026-06-03 | |
| 詢價(jià) |
VIP1年
|
陜西締都醫(yī)藥有限責(zé)任公司
|
2026-04-22 | |
| 詢價(jià) |
VIP7年
|
上海澤葉生物科技有限公司
|
2026-06-09 | |
| ¥2295.90 |
VIP3年
|
上海阿拉丁生化科技股份有限公司
|
2025-05-16 |